Achieve Life Sciences Inc
NASDAQ:ACHV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
US |
|
T
|
Terranet AB
STO:TERRNT B
|
SE |
|
JACCS Co Ltd
TSE:8584
|
JP |
|
Banaras Beads Ltd
NSE:BANARBEADS
|
IN |
|
S
|
Shanghai Kaytune Industrial Co Ltd
SZSE:301001
|
CN |
|
Alkem Laboratories Ltd
NSE:ALKEM
|
IN |
|
Arista Networks Inc
NYSE:ANET
|
US |
|
FNB Corp
NYSE:FNB
|
US |
|
Cloudflare Inc
NYSE:NET
|
US |
|
BLB Ltd
NSE:BLBLIMITED
|
IN |
|
P
|
Prosiebensat 1 Media SE
XETRA:PSM
|
DE |
|
Tilray Brands Inc
XETRA:2HQ0
|
CA |
|
Franklin Wireless Corp
NASDAQ:FKWL
|
US |
|
International Seaways Inc
NYSE:INSW
|
US |
|
hVIVO PLC
LSE:HVO
|
UK |
|
U
|
Unusual Machines Inc
AMEX:UMAC
|
US |
|
Lynas Rare Earths Ltd
XMUN:LYI
|
AU |
|
Changzhou Zhongying Science & Technology Co Ltd
SZSE:300936
|
CN |
|
China Reform Culture Holdings Co Ltd
SSE:600636
|
CN |
|
P
|
Polygiene Group AB
STO:POLYG
|
SE |
|
World Precision Machinery Ltd
SGX:B49
|
CN |
|
A
|
Akkhie Prakarn Public Company Limited
SET:AKP
|
TH |
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
